JUMP TO CONTENT
Medical record reading

What is Real World Evidence?

Posting date: 21/07/2025
Author: Inside ICON

What is Real World Evidence? Understanding its Role in Clinical Research

Real World Evidence (RWE) is a term increasingly being used within the healthcare and pharmaceutical industries, shaping critical decisions around drug approvals, patient treatments, and healthcare policies. But what exactly is Real World Evidence, and why has it become so important?

In this blog, we’ll demystify RWE, explore its applications, and highlight why organisations like ICON are pioneering its use in clinical research.

Real World Evidence Explained

Real World Evidence refers to clinical data collected outside the tightly controlled environment of randomised controlled trials (RCTs). While traditional clinical trials focus on assessing treatments under strict conditions, RWE is drawn from real-world settings such as patient registries, electronic health records, claims databases, wearable devices, and observational studies.

According to the U.S. Food and Drug Administration (FDA), Real World Evidence is defined as clinical evidence derived from analysing real-world data (RWD) regarding the usage, benefits, or risks of medical products. Real World Data itself refers to information related to patient health status and healthcare delivery routinely collected from various sources.

In short, RWE offers insights into how medicines and medical interventions perform in everyday clinical practice rather than in highly controlled environments.

How is Real World Evidence Collected?

Real World Evidence is generated from diverse sources, including:

  • Electronic Health Records (EHRs): Digital patient records containing comprehensive clinical data.
  • Patient Registries: Organised systems that collect uniform data to evaluate outcomes for populations defined by a specific disease, condition, or exposure. 
  • Claims and Billing Data: Records from insurance providers detailing healthcare services utilised, diagnosis codes, and prescribed treatments. 
  • Wearable and Mobile Devices: Continuous monitoring devices, such as fitness trackers and digital sensors, providing real-time health data. 
  • Observational Studies and Surveys: Research studies designed to observe and collect health outcomes without direct intervention by researchers.

Each source offers unique benefits, helping researchers understand patient behaviour, treatment effectiveness, long-term safety, and broader health outcomes.

Why is Real World Evidence Important?

Real World Evidence has become invaluable to healthcare stakeholders including regulators, healthcare providers, pharmaceutical companies, payers, and patients - offering numerous benefits:

Enhanced Decision-Making Real World Evidence complements traditional clinical trial data by providing additional context. Regulators such as the FDA, European Medicines Agency (EMA), and others are increasingly utilising RWE to inform their decisions about drug approvals, label expansions, and post-marketing surveillance.

Accelerated Drug Development RWE can streamline drug development, accelerating the time-to-market for innovative therapies. By leveraging existing real-world datasets, organisations can identify unmet medical needs, reduce the scope and duration of traditional clinical trials, and swiftly identify optimal patient populations.

Personalised Healthcare Real World Evidence facilitates personalised medicine by highlighting how different patient subgroups respond to therapies in real-life scenarios. This can support tailored treatment strategies, improving patient outcomes.

Cost Efficiency Generating Real World Evidence from existing data sources can be more cost-effective than conducting large-scale clinical trials. Pharmaceutical companies and healthcare providers can utilise RWE to optimise resource allocation, reduce healthcare costs, and enhance economic efficiencies.

Challenges & Limitations of Real World Evidence

While Real World Evidence holds tremendous potential, it is essential to acknowledge challenges and limitations inherent to RWE collection and interpretation:

Data Quality and Standardisation: Real-world data sources are heterogeneous, and inconsistencies in data collection methods and reporting can affect the quality and comparability of evidence generated.

Bias and Confounding Factors: Observational data often carries potential biases due to lack of randomisation, patient selection criteria, and missing information, complicating causality assessments.

Regulatory and Ethical Considerations: Regulators have specific requirements for the acceptability and robustness of RWE, necessitating careful adherence to ethical and privacy standards.

Organisations such as ICON play a critical role in addressing these challenges by applying rigorous scientific methodologies and quality standards to ensure reliability and compliance.

Future Outlook 

The role of Real World Evidence is rapidly expanding, especially with advancements in technology and data analytics. Experts predict significant growth in the utilisation of RWE in areas like oncology, rare diseases, chronic illnesses, and personalised therapies.

Regulatory bodies worldwide including the FDA and EMA are proactively exploring and implementing frameworks to integrate RWE into approval processes and post-marketing assessments. According to Deloitte, 94% of pharmaceutical leaders now consider RWE essential to their strategy, indicating the increasing importance of RWE in shaping future clinical research and drug approvals.

Moreover, digital innovations such as AI-powered analytics, blockchain technologies, and advanced health tracking devices are expected to further enhance the quality, transparency, and accessibility of Real World Evidence.

Conclusion: Why Real World Evidence Matters

Real World Evidence is a transformative force in modern clinical research. It bridges the gap between controlled trial settings and real-world clinical practice, offering essential insights that improve patient outcomes, inform regulatory decisions, and advance healthcare delivery.

At ICON, Real World Evidence helps to enable smarter, faster, and more patient-centric approaches to clinical development.

Understanding Real World Evidence is not only crucial for healthcare professionals and pharmaceutical companies but also vital for patients and the wider healthcare community. By embracing the potential of RWE, ICON and the industry at large are better positioned to deliver effective, safe, and personalised treatments - ultimately improving lives around the globe.

List #1

Related jobs at ICON

CRA II/Senior CRA

Salary

Location

Czech Republic, Prague

Department

Clinical Monitoring

Location

Prague

Remote Working

Office or Home

Business Area

ICON Full Service & Corporate Support

Job Categories

Clinical Monitoring

Job Type

Permanent

Description

We are currently seeking a Clinical Research Associate II to join our diverse and dynamic team. As a Clinical Research Associate II at ICON, you will play a pivotal role in designing and analyzing cli

Reference

JR138155

Expiry date

01/01/0001

Tereza Svobodova Read more Shortlist Save this role
Principal Auditor, Client Relationships QA

Salary

Location

US, Blue Bell (ICON)

Department

Full Service - Quality Assurance

Location

Blue Bell

Remote Working

Office or Home

Business Area

ICON Full Service & Corporate Support

Job Categories

Quality Assurance

Job Type

Permanent

Description

We are currently seeking a Principal Auditor Quality Assurance to join our diverse and dynamic team in Client Relationship Quality Assurance (CRQA). As a Principal Auditor CRQA at ICON, you will play

Reference

JR136146

Expiry date

01/01/0001

Muna Nelke

Author

Muna Nelke
Muna Nelke

Author

Muna Nelke
Read more Shortlist Save this role
Clinical Associate

Salary

Location

Canada, Montreal

Location

Montreal

Remote Working

Office or Home

Business Area

ICON Full Service & Corporate Support

Job Categories

Clinical Operations

Job Type

Permanent

Description

At ICON, it’s our people that set us apart. Our diverse teams enable us to become a better partner to our customers and help us to fulfil our mission to advance and improve patients’ lives.Our ‘Own It

Reference

JR136944

Expiry date

01/01/0001

Zach Hines

Author

Zach Hines
Zach Hines

Author

Zach Hines
Read more Shortlist Save this role
View all
List #1

Related stories

Two medics at ICON clinical research clinic
The Strategic Role of Site Selection and Activation in Clinical Trials

Teaser label

Industry

Content type

Blogs

Publish date

10/28/2025

Summary

Precision at the Outset: The Strategic Role of Site Selection and Activation in Clinical Trials The success of any clinical trial begins well before the first patient is enrolled. Behind every sit

Teaser label

Explore the critical role of site selection and activation in clinical trials.

Read more
Headshot of female
A Career Focused on Patients: Daniela's Journey at ICON

Teaser label

Our People

Content type

Blogs

Publish date

10/27/2025

Summary

Daniela’s Journey at ICON Daniela Gutierrez’s career at ICON has been a journey of transition, determination, and purpose. What began as a role in study start-up has evolved into a position deeply

Teaser label

Daniela shares insights into how collaboration, purpose, and innovation drive every part of her work.

Read more
Headshot of male
ICON Careers Spotlight: Chris Maguire, Director of Finance Business Partnering

Teaser label

Our People

Content type

Blogs

Publish date

10/15/2025

Summary

Chris Maguire’s Journey at ICON Over the past eight years at ICON, Chris Maguire has held six roles within the finance function, each expanding his expertise and sharpening his ability to support

Teaser label

Discover how Chris Maguire’s collaborative approach has shaped a rewarding career journey at ICON.

Read more
View all
List #1

Recently viewed jobs

View Jobs

Browse popular job categories below or search all jobs above